LENSAR Past Earnings Performance
Past criteria checks 0/6
LENSAR has been growing earnings at an average annual rate of 3.6%, while the Medical Equipment industry saw earnings growing at 12% annually. Revenues have been growing at an average rate of 11.8% per year.
Key information
3.6%
Earnings growth rate
57.4%
EPS growth rate
Medical Equipment Industry Growth | 8.9% |
Revenue growth rate | 11.8% |
Return on equity | -45.5% |
Net Margin | -34.0% |
Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Market Might Still Lack Some Conviction On LENSAR, Inc. (NASDAQ:LNSR) Even After 28% Share Price Boost
Oct 24LENSAR (NASDAQ:LNSR) Is In A Good Position To Deliver On Growth Plans
Sep 12LENSAR, Inc. (NASDAQ:LNSR) Doing What It Can To Lift Shares
Jul 16Here's Why Shareholders May Want To Be Cautious With Increasing LENSAR, Inc.'s (NASDAQ:LNSR) CEO Pay Packet
May 01LENSAR, Inc.'s (NASDAQ:LNSR) Shares Leap 33% Yet They're Still Not Telling The Full Story
Feb 22Here's Why We're Watching LENSAR's (NASDAQ:LNSR) Cash Burn Situation
Jan 24Not Many Are Piling Into LENSAR, Inc. (NASDAQ:LNSR) Just Yet
Dec 20Here's Why We're A Bit Worried About LENSAR's (NASDAQ:LNSR) Cash Burn Situation
Oct 21Investors Continue Waiting On Sidelines For LENSAR, Inc. (NASDAQ:LNSR)
Sep 13This Broker Just Slashed Their LENSAR, Inc. (NASDAQ:LNSR) Earnings Forecasts
Mar 21Will LENSAR (NASDAQ:LNSR) Spend Its Cash Wisely?
Mar 18Here's Why We're Not Too Worried About LENSAR's (NASDAQ:LNSR) Cash Burn Situation
Nov 01LENSAR GAAP EPS of -$0.67, revenue of $8M
Aug 08LENSAR (NASDAQ:LNSR) Is In A Good Position To Deliver On Growth Plans
Mar 23We Think LENSAR (NASDAQ:LNSR) Can Afford To Drive Business Growth
Jul 28LENSAR EPS misses by $0.23, beats on revenue
May 05What You Need To Know About LENSAR, Inc.'s (NASDAQ:LNSR) Investor Composition
Feb 25We're Keeping An Eye On LENSAR's (NASDAQ:LNSR) Cash Burn Rate
Jan 03Revenue & Expenses Breakdown
How LENSAR makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
30 Sep 24 | 49 | -17 | 27 | 5 |
30 Jun 24 | 45 | -13 | 26 | 6 |
31 Mar 24 | 45 | -12 | 28 | 6 |
31 Dec 23 | 42 | -14 | 27 | 6 |
30 Sep 23 | 40 | -13 | 27 | 6 |
30 Jun 23 | 38 | -18 | 28 | 6 |
31 Mar 23 | 34 | -18 | 28 | 9 |
31 Dec 22 | 35 | -20 | 27 | 12 |
30 Sep 22 | 36 | -21 | 26 | 14 |
30 Jun 22 | 37 | -23 | 26 | 15 |
31 Mar 22 | 37 | -21 | 24 | 14 |
31 Dec 21 | 34 | -20 | 24 | 12 |
30 Sep 21 | 32 | -23 | 27 | 11 |
30 Jun 21 | 30 | -21 | 27 | 10 |
31 Mar 21 | 28 | -21 | 25 | 9 |
31 Dec 20 | 26 | -20 | 24 | 8 |
30 Sep 20 | 27 | -15 | 20 | 3 |
30 Jun 20 | 27 | -16 | 18 | 5 |
31 Mar 20 | 29 | -15 | 18 | 5 |
31 Dec 19 | 31 | -15 | 17 | 4 |
31 Dec 18 | 24 | -14 | 16 | 3 |
Quality Earnings: LNSR is currently unprofitable.
Growing Profit Margin: LNSR is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: LNSR is unprofitable, but has reduced losses over the past 5 years at a rate of 3.6% per year.
Accelerating Growth: Unable to compare LNSR's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: LNSR is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (12.9%).
Return on Equity
High ROE: LNSR has a negative Return on Equity (-45.53%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2024/12/23 03:02 |
End of Day Share Price | 2024/12/23 00:00 |
Earnings | 2024/09/30 |
Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
LENSAR, Inc. is covered by 3 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|---|
Michael Gorman | BTIG |
Frank Takkinen | Lake Street Capital Markets, LLC |
Richard Newitter | Leerink Partners LLC |